{
    "ticker": "CADL",
    "name": "Cadrenal Therapeutics, Inc.",
    "description": "Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare and chronic diseases. Founded in 2018, Cadrenal is committed to addressing unmet medical needs through its proprietary drug development programs. The company's lead product candidate, CAD-101, is an investigational therapy designed to improve the treatment outcomes for patients suffering from chronic kidney disease. Cadrenal's experienced team of scientists and clinicians leverage cutting-edge technology and research methodologies to advance their pipeline, aiming to bring new hope to patients and their families. The company prioritizes patient-centric approaches in its research and development processes, ensuring that the voices and needs of patients are at the forefront of their initiatives. Cadrenal is also focused on strategic partnerships and collaborations to enhance its capabilities and accelerate its drug development efforts. With a mission to transform the lives of patients through innovative therapies, Cadrenal is dedicated to making a meaningful impact in the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Austin, Texas, USA",
    "founded": "2018",
    "website": "https://www.cadrenaltherapeutics.com",
    "ceo": "Dr. Robert J. Henneman",
    "social_media": {
        "twitter": "https://twitter.com/CadrenalTx",
        "linkedin": "https://www.linkedin.com/company/cadrenal-therapeutics"
    },
    "investor_relations": "https://www.cadrenaltherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Dr. Robert J. Henneman",
            "position": "CEO"
        },
        {
            "name": "David H. O\u2019Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CAD-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cadrenal Therapeutics, Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Cadrenal Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for chronic and rare diseases.",
        "keywords": [
            "Cadrenal Therapeutics",
            "Biopharmaceuticals",
            "Chronic Kidney Disease",
            "Innovative Therapies",
            "CAD-101"
        ]
    },
    "faq": [
        {
            "question": "What does Cadrenal Therapeutics focus on?",
            "answer": "Cadrenal Therapeutics focuses on developing therapies for patients with rare and chronic diseases."
        },
        {
            "question": "Who is the CEO of Cadrenal Therapeutics?",
            "answer": "Dr. Robert J. Henneman is the CEO of Cadrenal Therapeutics, Inc."
        },
        {
            "question": "Where is Cadrenal Therapeutics headquartered?",
            "answer": "Cadrenal Therapeutics is headquartered in Austin, Texas, USA."
        },
        {
            "question": "What is Cadrenal's lead product candidate?",
            "answer": "Cadrenal's lead product candidate is CAD-101, targeting chronic kidney disease."
        },
        {
            "question": "When was Cadrenal Therapeutics founded?",
            "answer": "Cadrenal Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "AMRN",
        "RPTX",
        "CRBP"
    ],
    "related_stocks": [
        "VRTX",
        "BIIB",
        "GILD",
        "REGN"
    ]
}